Comparison of TOP40 market cap of China and u.S. pharmaceutical listed companies in 2019

Author:In recent years, China's pharmaceutical enterprises have been the focus of market attention, especially the rapid development of innovative chinese and biological drugs, driving the rise of the entire industryfrom the data, domestic A-share listed companies belong to the pharmaceutical sector of nearly 300 enterprises, but only seven companies have a market capitalization of more than 100 billion, and in the United States listed pharmaceutical company data, the market value of more than 100 billion is "common practice"U.S.-listed pharmaceutical companies China, Johnson and Johnson, Pfizer, Mersadong and so on are old and strong enterprises, from research and development to production to sales, several key steps have a perfect and close industrial chain, and the overall pattern gradient is obviousIn contrast, China has only part of the head ladder, the rest of the enterprise development is more average, there is a certain development of the "ceiling"data show that the U.Sdrug company Johnson and Johnson as TOP1 market value of China's pharmaceutical company TOP1 market value of about 6 times, the difference between revenue and net profit is more, research and development investment is even more difficult to matchBut a share has Yunnan white medicine, tablets and other major Chinese medicine characteristics of the track, but also reflects the differences in the drug environment between China and the United StatesAccording to the pharmaceutical Rubik's Cube data, the 2019 revenue, net profit and market value of Listed companies in China and the United States compared with TOP40, the specific situation is as follows: